A Study of HM11260C in Healthy Male Subject

Primary Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single subcutaneous dose of HM11260C in healthy male subjects.

Inclusion criteria

• Healthy male volunteers, age range 20 to 45 years
• Weight>50 and < 90kg, Body mass index of >18 and <27 Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study

Exclusion criteria

• Acute disease within 1 month prior to start of study drug administration
• Has previously disease which affect drug absorption, distribution, metabolism, excretion (e.g., inflammatory gastric disease, gastric or intestinal ulcer, hepatic disease, renal disease)
• History or presence of clinically significant and active cardiovascular, pulmonary, renal, endocrine, hematological, gastrointestinal, central nervous system, psychiatric disorder, autoimmune disease, or malignant tumor
• Has unsuitable clinical test results through the medical checkup, within 35 days prior to start of administration of study drug (medical history, physical examination, ECG, laboratory test)
• Laboratory test results

• AST (sGOT) or ALT (sGPT) > 1.25Xupper normal limit
• Total bilirubin > 1.5Xupper normal limit
• Absolute Neutrophil Count < 1500 mm2
• History or presence of clinically significant allergic disease (including mild allergic rhinitis and allergic dermatitis which is not necessary to medication)
• Prior exposure to products related to Exenatide
• Use of any prescription medication within 14 days prior to Day 1
• Use of any medication within 7 days prior to Day 1 (over-the-counter medication, herbal products, nutrient, vitamins)
• Subject who can't eat standard meal received by Korea University Anam Hospital
• Donor of whole blood for transfusion within 60 days prior to start of study drug administration or donor of apheresis within 20 days or Receiver of blood transfusion within 1 month
• Participation in another clinical study within 60 days prior to start of study drug administration
• Taking Caffein(> 5cups/ day) or alcohol abuse (> 30g/ day) or excessive smoker(> 10 Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study